<?xml version="1.0" encoding="UTF-8"?>
<p>As shown in 
 <xref rid="pathogens-08-00176-t003" ref-type="table">Table 3</xref>, while DAA use is common, a small number of patients have been treated with IFN and/or RBV and DAAs. Based on the known side effects of IFN and particularly the hematologic side effects of RBV [
 <xref rid="B3-pathogens-08-00176" ref-type="bibr">3</xref>], we suggest the adoption of IFN-free/RBV-free antiviral therapies for HCV-induced glomerular disease.
</p>
